Neoadjuvant chemotherapy technology becomes the focus of gastric cancer research At the 7th China Congress of Medical Oncology and the 2nd China Congress of Oncologists held on July 6, Prof. Ji Jiafu, President of Peking University Cancer Hospital, suggested that conducting high-quality clinical research on neoadjuvant chemotherapy, selecting gastric cancer patients who are most likely to benefit from it by accurately assessing the pre-treatment risks, applying existing high-efficiency and low-toxicity novel drugs preoperatively, so as to make the progressive It will be one of the main directions of future gastric cancer research to reduce the lesion size of stage gastric cancer, reduce the invasion of the tumor and its lymph nodes to the surrounding organs, and thus increase the rate of radical resection by surgery. At present, about 40% of the total number of gastric cancer patients in China account for the total number of gastric cancer patients worldwide, and the incidence rate of gastric cancer in China will climb by 1.6% per year from 2010 to 2015. Meanwhile, the low awareness of gastric cancer screening in China makes the detection rate of early gastric cancer only 10%, while 80% of gastric cancer patients are in the progressive stage, and the treatment effect of the latter determines the overall efficacy of gastric cancer in China. Neoadjuvant chemotherapy, also called preoperative chemotherapy, refers to the treatment means of systemic chemotherapy given before local treatment such as surgery or radiotherapy for malignant tumors. Ji Jiafu said that there is now an industry consensus that for patients with progressive gastric cancer, even with expanded resection and lymph node dissection, surgery alone cannot achieve biologically meaningful cure. Given the important role neoadjuvant chemotherapy has played in the treatment of solid tumors such as breast and lung cancer, its use in gastric cancer patients is also highly anticipated. According to Ji Jiafu, accurate preoperative staging and efficacy evaluation are the keys to the future neoadjuvant chemotherapy treatment process. Currently, in terms of preoperative staging, special emphasis is placed on the application of new tools such as diagnostic laparoscopic techniques and abdominal free cell examination, and PET/CT examination can be considered in centers with conditions. In terms of efficacy evaluation, a comprehensive three-dimensional efficacy evaluation criteria including traditional morphological evaluation (enhanced CT, upper gastrointestinal imaging, etc.), emerging functional evaluation (PET/CT and functional MRI, etc.), and molecular biology evaluation methods are recommended.